T3 Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
31
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$502M
- Investors
-
1
T3 Pharmaceuticals General Information
Description
Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system to treat solid cancer tumors, enabling healthcare providers to improve the lives of patients and cure them.
Contact Information
Website
www.t3pharma.com(Operating Subsidiary)
Corporate Office
- Hegenheimermattweg 167A
- 4123 Allschwil
- Switzerland
Corporate Office
- Hegenheimermattweg 167A
- 4123 Allschwil
- Switzerland
T3 Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 22-Nov-2023 | $502M | Completed | Clinical Trials - Phase 1 | ||
| 9. Later Stage VC | 22-Jul-2020 | Completed | Clinical Trials - Phase 1 | |||
| 8. Early Stage VC | 26-Sep-2019 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 28-May-2019 | Completed | Clinical Trials - Phase 1 | |||
| 6. Accelerator/Incubator | 30-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 5. Angel (individual) | 28-Nov-2016 | Completed | Startup | |||
| 4. Grant | 01-Jan-2016 | Completed | Startup | |||
| 3. Grant | Completed | Startup | ||||
| 2. University Spin-Out | 01-May-2015 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
T3 Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B Preference | ||||||||
| Ordinary |
T3 Pharmaceuticals Comparisons
Industry
Financing
Details
T3 Pharmaceuticals Competitors (59)
One of T3 Pharmaceuticals’s 59 competitors is Meditope Biosciences, a Formerly VC-backed company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| Anaveon | Venture Capital-Backed | Basel, Switzerland | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| RootPath | Venture Capital-Backed | Framingham, MA | ||||
| Memgen | Venture Capital-Backed | Houston, TX |
T3 Pharmaceuticals Patents
T3 Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022244124-A1 | Pharmaceutical combinations for treating cancer | Pending | 25-Mar-2021 | ||
| AU-2022244124-A9 | Pharmaceutical combinations for treating cancer | Pending | 25-Mar-2021 | ||
| CA-3210774-A1 | Pharmaceutical combinations for treating cancer | Pending | 25-Mar-2021 | ||
| EP-4313310-A1 | Pharmaceutical combinations for treating cancer | Pending | 25-Mar-2021 | ||
| EP-4314036-A1 | Pharmaceutical combinations for treating cancer | Pending | 25-Mar-2021 | A61P35/00 |
T3 Pharmaceuticals Signals
T3 Pharmaceuticals Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BaseLaunch | Accelerator/Incubator | |||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| Gebert Rüf Foundation | Accelerator/Incubator | |||
| Innosuisse | Government | |||
| Reference Capital | Venture Capital | Minority |
T3 Pharmaceuticals FAQs
-
When was T3 Pharmaceuticals founded?
T3 Pharmaceuticals was founded in 2015.
-
Where is T3 Pharmaceuticals headquartered?
T3 Pharmaceuticals is headquartered in Allschwil, Switzerland.
-
What is the size of T3 Pharmaceuticals?
T3 Pharmaceuticals has 31 total employees.
-
What industry is T3 Pharmaceuticals in?
T3 Pharmaceuticals’s primary industry is Drug Discovery.
-
Is T3 Pharmaceuticals a private or public company?
T3 Pharmaceuticals is a Private company.
-
What is the current valuation of T3 Pharmaceuticals?
The current valuation of T3 Pharmaceuticals is .
-
What is T3 Pharmaceuticals’s current revenue?
The current revenue for T3 Pharmaceuticals is .
-
How much funding has T3 Pharmaceuticals raised over time?
T3 Pharmaceuticals has raised $41.8M.
-
Who are T3 Pharmaceuticals’s investors?
BaseLaunch, Boehringer Ingelheim Venture Fund, Gebert Rüf Foundation, Innosuisse, and Reference Capital are 5 of 11 investors who have invested in T3 Pharmaceuticals.
-
Who are T3 Pharmaceuticals’s competitors?
Meditope Biosciences, Anaveon, Inovio Pharmaceuticals, RootPath, and Memgen are some of the 59 competitors of T3 Pharmaceuticals.
-
When was T3 Pharmaceuticals acquired?
T3 Pharmaceuticals was acquired on 22-Nov-2023.
-
Who acquired T3 Pharmaceuticals?
T3 Pharmaceuticals was acquired by Boehringer Ingelheim.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process